Description of the medicine: Parmidinum (Parmidinum)
Bis-N-methylcarbamic ester of 2, 6-bis-hydroxymethylpyridine, or 2, 6-pyridinyl-bis (methyl-N-methylcarbamate).
Synonyms: Anginine, Pyridinocarbamate, Prodectin, Acesterol, Andil, Anginin, Angiovital, Angioxine, Angioxyl, Aterofal, Aterokin, Atover, Cicloven, Colesterinex, Duaxol, Duvaline, Eluen, Exibral, Garparol, Katrombin, Prodectin, Pyridinolcarbamat, Ravecil, Sospitan, Vasagin, Vasapril, Vasocil, Vasoverin, Veranterol and others.
White or almost white crystalline powder. It is slightly soluble in water, it is difficult - in alcohol.
Parmidin has angioprotective activity, reduces vascular permeability, promotes the restoration of impaired microcirculation in pathological processes. To a large extent this is due to the effect on the kinin-kallikrein system, especially with a decrease in bradykinin activity. It also reduces the aggregation of platelets, stimulates fibrinogenesis.
Initially, parmidine (anginin) was suggested as an antisclerotic. As a bradykinin antagonist, it reduces the reduction in endothelial cells of the arteries, as well as the gaps between them, and thus prevents penetration of the inner shell of the vessels of atherogenic lipoproteins. Possessing anti-inflammatory activity, parmidin also reduces the edema of endothelial cells, preventing lipid infiltration of the inner shell of the vessels, and promotes the reverse development of infiltrative changes in atherosclerosis. It also has moderate hypocholesterolemic activity.
As an independent antisclerotic drug, parmidin is not currently used, but it is widely used as a complex therapy for the treatment of atherosclerosis of the vessels of the brain, heart, limbs, atherosclerotic and diabetic angiopathy, retinal vein thrombosis, obliterating endarteritis, and trophic ulcers of the extremities. The best effect was observed in lesions of peripheral vessels, especially vessels of the lower extremities, with diabetic angiopathies, mainly diabetic retinopathy. There is evidence of a positive effect of the drug on the state of the stomach and pancreas in diabetes mellitus, as well as the advisability of using parmidin (prodeectin) in the complex treatment of patients with pulmonary tuberculosis. The drug accelerates the disappearance of symptoms of intoxication and resorption of infiltrates in the lungs. Improves the tolerability of anti-tuberculosis chemotherapeutic drugs.
Parmidin should be combined with vitamins, enzymes, coenzymes, and if necessary with antidiabetic drugs (for diabetic angiopathies). There was a marked tendency to normalize lipid metabolism in chronic ischemic heart disease when taking parmidin (prodectin) in combination with lipoic acid.
Assign parmidin inside, starting with 0.25 g (1 tablet) 3 - 4 times a day. Then, with good tolerability, increase the dose to 0.75 g (3 tablets) 3 to 4 times a day. Usually the daily dose is 1 - 2 g. The course of treatment - from 2 to 6 months or more.